Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 651-656

  Ma, Nan ^a   Li, Li Wei ^a   Cheng, Jing Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Clinical outcome; Polymorphism; Renal cell carcinomas; Vascular endothelial growth factor

Indexed keywords

GENOMIC DNA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENOTYPE; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; VASCULOTROPIN GENE;

EID: 84918822133     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2798     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
3. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
4. Cao Q, Wang J, Zhang M, et al: Genetic Variants in RKIP Are Associated with Clear Cell Renal Cell Carcinoma Risk in a Chinese Population. PLoS One 9: e109285, 2014.
5. Mu HJ, Zou J, Xie P, Xu ZQ, Ruan J, Yang SD and Yin Y: Association of leptin receptor Lys109Arg and Gln223Arg polymorphisms with increased risk of clear cell renal cell carcinoma. Asian Pac J Cancer Prev 15: 4211-4215, 2014.
6. Patard JJ, Pouessel D, Bensalah K and Culine S: Targeted therapy in renal cell carcinoma. World J Urol 26: 135-140, 2008.
7. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
8. Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93: 1493-1495, 1996.
9. Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232-1235, 2000.
10. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293-298, 2004.
11. Luo T, Chen L, He P, et al: Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population. Asian Pac J Cancer Prev 14: 2433-2437, 2013.
12. Sivaprasad S, Govardhan B, Harithakrishna R, et al: Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma. Pancreatology 13: 267-272, 2013.
13. Mandal RK, Yadav SS, Panda AK and Khattri S: Vascular endothelial growth factor 936 c>T polymorphism increased oral cancer risk: evidence from a meta-analysis. Genet Test Mol Biomarkers 17: 543-547, 2013.
14. He D, Lu W, Chang K, et al: Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: a meta-analysis. Gene 518: 296-302, 2013.
15. Garcia-Donas J, Rodriguez-Antona C and Jonasch E: Molecular markers to predict response to therapy. Semin Oncol 40: 444-458, 2013.
16. Vrdoljak E, Rini B, Schmidinger M, et al: Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24: 431-440, 2013.
17. Jäkel CE, Hauser S, Rogenhofer S, et al: Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol 2012: 473245, 2012.
18. Kawai Y, Sakano S, Korenaga Y, Eguchi S and Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52: 1147-1155, 2007.
19. Sáenz-López P, Vazquez F, Cozar JM, et al: VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol 74: 98-103, 2013.
20. Edge SB, Byrd DR, Compton CC, et al (eds): Kidney. In: AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, pp2010479-2010489, 2010.
21. Abe A, Sato K, Habuchi T, et al: Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med 198: 181-190, 2002.
22. Salven P, Teerenhovi L and Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90: 3167-3172, 1997.
23. Martinez-Fierro ML, Garza-Veloz I, Rojas-Martinez A, et al: Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer. Cancer Biomark 13: 235-241, 2013.
24. Chen P, Zhu J, Liu DY, et al: Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol 31: 775, 2014.
25. Oh SY, Kwon HC, Kim SH, et al: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13: 43, 2013.
26. Absenger G, Szkandera J, Stotz M, et al: A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog 52 (Suppl 1): E96-E102, 2013.
27. Hefler LA, Mustea A, Könsgen D, et al: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13: 898-901, 2007.
28. Shahbazi M, Fryer AA, Pravica V, et al: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13: 260-264, 2002.
29. Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, et al: Vascular endothelial growth factor -634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep 8: 1242-1250, 2013.
30. Supic G, Jovic N, Zeljic K, Kozomara R and Magic Z: Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol 48: 1171-1177, 2012.
31. Jin Q, Hemminki K, Enquist K, et al: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11: 3647-3653, 2005.